Publications by authors named "Daniel Rutrick"
Background: Few studies investigate the natural history of patients on long-term treatment for opioid use disorder (OUD). We evaluated the long-term efficacy, safety, and tolerability experience of monthly extended-release buprenorphine (BUP-XR) in participants seeking treatment for OUD, via integrated analysis of phase 3 studies.
Methods: Study 1 was a 24-week randomized, double-blind, placebo-controlled trial of participants receiving monthly injections of BUP-XR (300 mg × 2, 100 mg × 4 [n = 203] or 300 mg × 6 [n = 201]) or placebo (n = 100).
Article Synopsis
- BUP-XR is the first FDA-approved monthly injectable medication for treating moderate to severe opioid use disorder, aimed at evaluating its long-term safety, tolerability, and effectiveness.
- A total of 669 participants were involved, receiving up to 12 injections, with a significant number reporting mild to moderate adverse effects, particularly at the injection site.
- After 12 months, a substantial percentage of participants remained abstinent and the study confirmed sustained clinical benefits and a better safety profile over time, highlighting reduced side effects in the second half of treatment.
Introduction: To determine if mavoglurant (modified release) as an augmentation therapy to selective serotonin reuptake inhibitors (SSRIs) could have beneficial effects reducing Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score in patients with obsessive-compulsive disorder (OCD) resistant to SSRI treatment.
Methods: This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 2 study. Patients remained on their SSRI treatment and mavoglurant or placebo was added on.